

Claims

- [Claim 1] Ammonium salt of
2-[4-[(5,6-diphenylpyrazin-2-yl)-propan-2-ylamino]butoxy]acetic acid,
or pharmaceutically acceptable hydrate or solvate thereof.
- [Claim 2] Arginate salt of
2-[4-[(5,6-diphenylpyrazin-2-yl)-propan-2-ylamino]butoxy]acetic acid,
or pharmaceutically acceptable hydrate or solvate thereof.
- [Claim 3] Calcium salt of
2-[4-[(5,6-diphenylpyrazin-2-yl)-propan-2-ylamino]butoxy]acetic acid,
or pharmaceutically acceptable hydrate or solvate thereof.
- [Claim 4] Choline salt of
2-[4-[(5,6-diphenylpyrazin-2-yl)-propan-2-ylamino]butoxy]acetic acid,
or pharmaceutically acceptable hydrate or solvate thereof.
- [Claim 5] 1,2-Ethanedisulfonate salt of
2-[4-[(5,6-diphenylpyrazin-2-yl)-propan-2-ylamino]butoxy]acetic acid,
or pharmaceutically acceptable hydrate or solvate thereof.
- [Claim 6] Histidine salt of
2-[4-[(5,6-diphenylpyrazin-2-yl)-propan-2-ylamino]butoxy]acetic acid,
or pharmaceutically acceptable hydrate or solvate thereof.
- [Claim 7] Potassium salt of
2-[4-[(5,6-diphenylpyrazin-2-yl)-propan-2-ylamino]butoxy]acetic acid,
or pharmaceutically acceptable hydrate or solvate thereof.
- [Claim 8] Sodium salt of
2-[4-[(5,6-diphenylpyrazin-2-yl)-propan-2-ylamino]butoxy]acetic acid,
or pharmaceutically acceptable hydrate or solvate thereof.
- [Claim 9] Tromethamine salt of
2-[4-[(5,6-diphenylpyrazin-2-yl)-propan-2-ylamino]butoxy]acetic acid,
or pharmaceutically acceptable hydrate or solvate thereof.
- [Claim 10] A crystal of the ammonium salt according to claim 1, showing
diffraction peaks in its X-ray powder diffraction spectrum at least at the
following angles of diffraction 2θ : 8.4° , 14.7° , 15.2° , 16.3° and 21.3° ,
preferably 2θ : 8.4° , 11.2° , 14.7° , 15.2° , 16.3° and 21.3° , wherein the X-
ray powder diffraction diagram is obtained by using Cu K α radiation.
- [Claim 11] A crystal of the L-arginine salt according to claim 2, showing
diffraction peaks in its X-ray powder diffraction spectrum at least at the
following angles of diffraction 2θ : 5.5° , 11.1° , 19.3° , 20.2° and 22.4° ,
preferably 2θ : 5.5° , 11.1° , 19.3° , 19.8° , 20.2° , 22.4° and 23.1° , wherein

the X-ray powder diffraction diagram is obtained by using Cu K α radiation.

- [Claim 12] A crystal of the calcium salt according to claim 3, showing diffraction peaks in its X-ray powder diffraction spectrum at least at the following angles of diffraction 2 θ : 4.8°, 8.7°, 9.7°, 15.2° and 18.5°, preferably 2 θ : 4.8°, 8.7°, 9.7°, 11.1°, 15.2°, 16.0°, 18.1°, 18.5° and 23.4°, wherein the X-ray powder diffraction diagram is obtained by using Cu K α radiation.
- [Claim 13] A crystal of the choline salt according to claim 4, showing diffraction peaks in its X-ray powder diffraction spectrum at least at the following angles of diffraction 2 θ : 9.5°, 10.4°, 15.0°, 17.8° and 21.5°, preferably 2 θ : 9.5°, 10.4°, 13.5°, 15.0°, 17.8°, 18.6°, 18.9°, 20.5° and 21.5°, wherein the X-ray powder diffraction diagram is obtained by using Cu K α radiation.
- [Claim 14] A crystal of the 1,2-ethanedisulfonate salt according to claim 5, showing diffraction peaks in its X-ray powder diffraction spectrum at least at the following angles of diffraction 2 θ : 6.8°, 8.6°, 19.4°, 22.5° and 25.6°, preferably 2 θ : 6.8°, 8.6°, 10.1°, 12.7°, 16.2°, 18.3°, 19.4°, 22.5° and 25.6°, wherein the X-ray powder diffraction diagram is obtained by using Cu K α radiation.
- [Claim 15] A crystal of the L-histidine salt according to claim 6, showing diffraction peaks in its X-ray powder diffraction spectrum at least at the following angles of diffraction 2 θ : 9.4°, 15.3°, 18.9°, 21.0° and 24.2°, preferably 2 θ : 9.4°, 15.3°, 18.9°, 19.6°, 21.0°, 21.5°, 24.2°, 25.4°, 30.2° and 30.9°, wherein the X-ray powder diffraction diagram is obtained by using Cu K α radiation.
- [Claim 16] A crystal of the potassium salt according to claim 7, showing diffraction peaks in its X-ray powder diffraction spectrum at least at the following angles of diffraction 2 θ : 5.9°, 9.9°, 18.7°, 20.4° and 21.7°, preferably 2 θ : 5.9°, 7.3°, 9.3°, 9.9°, 10.4°, 13.2°, 18.7°, 20.4°, 21.7° and 22.5°, wherein the X-ray powder diffraction diagram is obtained by using Cu K α radiation.
- [Claim 17] A crystal of the potassium salt according to claim 7, showing diffraction peaks in its X-ray powder diffraction spectrum at least at the following angles of diffraction 4.0°, 4.5°, 8.2°, 14.6° and 17.2°, preferably 2 θ : 4.0°, 4.5°, 8.2°, 8.7°, 14.6° and 17.2°, wherein the X-ray powder diffraction diagram is obtained by using Cu K α radiation.
- [Claim 18] A crystal of the sodium salt according to claim 8, showing diffraction

peaks in its X-ray powder diffraction spectrum at least at the following angles of diffraction 2θ : 5.9, 9.9, 10.4, 18.6 and 20.4 preferably 2θ : 5.9°, 7.2°, 9.9°, 10.4°, 13.1°, 18.6°, 20.4°, 21.6° and 22.5°, wherein the X-ray powder diffraction diagram is obtained by using Cu K α radiation.

- [Claim 19] A crystal of the sodium salt according to claim 8, showing diffraction peaks in its X-ray powder diffraction spectrum at least at the following angles of diffraction 2θ : 3.8°, 7.9°, 10.3°, 19.8° and 20.7°, preferably 2θ : 3.8°, 7.9°, 9.4°, 9.9°, 10.3°, 18.0°, 19.8° and 20.7°, wherein the X-ray powder diffraction diagram is obtained by using Cu K α radiation.
- [Claim 20] A crystal of the tromethamine salt according to claim 9, showing diffraction peaks in its X-ray powder diffraction spectrum at least at the following angles of diffraction 2θ : 4.0°, 7.2°, 15.5°, 17.8° and 20.2°, preferably 2θ : 4.0°, 7.2°, 8.0°, 10.6°, 15.5°, 17.5°, 17.8°, 18.5° and 20.2°, wherein the X-ray powder diffraction diagram is obtained by using Cu K α radiation.
- [Claim 21] A crystal of the tromethamine salt according to claim 9, showing diffraction peaks in its X-ray powder diffraction spectrum at least at the following angles of diffraction 2θ : 3.5°, 10.4°, 15.9°, 17.1° and 20.6°, preferably 2θ : 3.5°, 10.4°, 15.9°, 17.1°, 17.6°, 18.3°, 19.9°, 20.6°, 21.9° and 24.0°, wherein the X-ray powder diffraction diagram is obtained by using Cu K α radiation.
- [Claim 22] A pharmaceutical composition containing the salt or the crystal according to any one of Claims 1 to 21 as an active ingredient.
- [Claim 23] The invention described herein.